SCHEMBL4539666

SCHEMBL4539666

O=[N+]([O-])c1ccc2ccc3ccc(O)c4ccc1c2c34

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSB P07858 4/20 0.59
CTSH P09668 1/20 0.53
ALDH1A1 P00352 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
MAPT P10636 3/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
LMNA P02545 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
CASP6 P55212 2/20 0.46
KDM4E B2RXH2 1/20 0.46
BRD4 O60885 1/20 0.46
HSP90AA1 P07900 1/20 0.46
CHRM1 P11229 1/20 0.46
DRD2 P14416 1/20 0.46
ALOX12 P18054 1/20 0.46
ADRA2B P18089 1/20 0.46
ADRA2C P18825 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30739459 1.00 CTSB (0.59) CTSBCTSHALDH1A1SMN1; SMN2MAPT
SCHEMBL28772861 1.00 CTSB (0.59) CTSBCTSHALDH1A1SMN1; SMN2MAPT
SCHEMBL1804954 0.88 TDP1 (0.50) CTSBCTSHALDH1A1SMN1; SMN2NPC1
SCHEMBL967910 0.88 TDP1 (0.50) CTSBCTSHALDH1A1SMN1; SMN2NPC1
SCHEMBL29450698 0.88 TDP1 (0.50) CTSBCTSHALDH1A1SMN1; SMN2NPC1
SCHEMBL7998423 0.84 CTSB (0.50) CTSBCTSHALDH1A1SMN1; SMN2MAPT
SCHEMBL16593674 0.81 HPRT1 (0.49) CTSBCTSHALDH1A1MAPTNPC1
SCHEMBL29403406 0.81 HPRT1 (0.49) CTSBCTSHALDH1A1MAPTNPC1
1-Nitropyrene SCHEMBL339725 0.81 ALDH1A1 (0.57) CTSBALDH1A1SMN1; SMN2MAPTNPC1
1-Nitropyrene SCHEMBL29450697 0.81 ALDH1A1 (0.57) CTSBALDH1A1SMN1; SMN2MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2846788-A1 USE OF COMPOUNDS FOR THE TREATMENT OF PAIN Akron Molecules AG (AT) 2015-03-18 EP disclosed
US-20140349969-A1 COMPOUNDS AND METHODS FOR TREATING PAIN AKRON MOLECULES AG (AT) 2014-11-27 US disclosed
EP-2674161-A1 FMO3 inhibitors for treating pain Akron Molecules GmbH (AT) 2013-12-18 EP disclosed
CN-103415286-A Compounds and methods for treating pain AKRON MOLECULES GMBH 2013-11-27 CN disclosed
WO-2013167743-A1 USE OF COMPOUNDS FOR THE TREATMENT OF PAIN AKRON MOLECULES GMBH (AT) 2013-11-14 WO disclosed
US-20130252924-A1 Compounds and Methods for Treating Pain AKRON MOLECULES GMBH (AT) 2013-09-26 US disclosed
EP-2637649-A2 COMPOUNDS AND METHODS FOR TREATING PAIN Akron Molecules GmbH (AT) 2013-09-18 EP disclosed
WO-2012062925-A2 COMPOUNDS AND METHODS FOR TREATING PAIN AKRON MOLECULES GMBH (AT) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140349969-A1 COMPOUNDS AND METHODS FOR TREATING PAIN TRPV1, ACHE, OPRL1 CTSB 345/4885CTSH 489/4885ALDH1A1 730/4885
US-20130252924-A1 Compounds and Methods for Treating Pain TRPV1, ACHE, OPRL1 CTSB 345/4885CTSH 489/4885ALDH1A1 730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.